BiotechTube

bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Carcinoid Tumor

Conditions

Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor

Trial Timeline

Jun 8, 2005 → Feb 1, 2016

NCT ID
NCT00227617

About bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin

bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin is a phase 2/3 stage product being developed by Sanofi for Gastrointestinal Carcinoid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT00227617. Target conditions include Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer.

What happened to similar drugs?

8 of 20 similar drugs in Gastrointestinal Carcinoid Tumor were approved

Approved (8) Terminated (3) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Mycophenolate SodiumNovartisApproved
✅myforticNovartisApproved
✅Imatinib MesylateNovartisApproved
✅Imatinib mesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
15
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00227617Phase 2/3Terminated

Competing Products

20 competing products in Gastrointestinal Carcinoid Tumor

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35